Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Hope Rekindled: The Remarkable Journey of a Pakistani Multiple Myeloma Patient in China
Hope Rekindled: The Remarkable Journey of a Pakistani Multiple Myeloma Patient in China
Hope of patient
“When I first arrived, I couldn’t walk and had a lot of pain in my chest and back. Now, I don’t have these symptoms anymore, and I can walk for more than ten minutes every day.”
Meet Julian, a patient from Pakistan who faced the daunting challenge of a relapse in his battle against Multiple Myeloma. Despite undergoing various treatments, relief seemed elusive.
Julian’s wife stumbled upon groundbreaking research published by Xuzhou Medical University, highlighting innovative cell therapy for Multiple Myeloma developed by the Tumor Biotherapy Research Institute and affiliated hospitals.
Seeking further treatment, Julian and his wife embarked on a journey to Xuzhou Medical University Affiliated Hospital. Upon arrival, thorough examinations were conducted to assess his condition and formulate a tailored treatment plan.
Julian underwent T-cell collection at the Hematology Department’s Cell Collection Room, with the harvested cells processed into CAR-T cells by Xuzhou Medical University’s Cancer Research Institute. Two weeks later, he received an infusion of immune cells (CD19CAR-T cells, BCMACAR-T cells).
A month later, bone marrow cytology revealed complete remission of the primary disease. His attending physician continued medical observations, confirming positive treatment outcomes through comprehensive examinations.
“Previously, I couldn’t sit like this, and walking was very difficult. It was also very uncomfortable to lie down.”
”After receiving CAR-T treatment, you can see that I can now sit normally, walk normally, and my mobility is gradually increasing.
My improvement is very significant.”
From treatment initiation to Julian’s discharge and return home, the entire process took just one and a half months.
Julian’s journey stands as a beacon of hope, showcasing the transformative potential of innovative medical interventions in the fight against Multiple Myeloma.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Miracle Unfolds: Zhejiang University Hospital’s Custom CRISPR/Cas9 Gene Editing + CAR-T Cell Therapy Rebirths Patients
🌟 Miracle Unfolds: Zhejiang University Hospital’s Custom CRISPR/Cas9 Gene Editing + CAR-T Cell Therapy Rebirths Patients 🌟
👨👧👦 (“I want to live to see my child go to university!”)👨👧👦
CAR-T Cell Therapy Patient
🎓 This heartfelt cry came from Mr. Sun, a 40-year-old patient from Guangzhou, who faced the formidable challenge of diffuse large B-cell lymphoma, a common adult lymphoma type.
🔬14 rounds of chemotherapy, 20 rounds of radiotherapy, total gastrectomy… For two years,
Mr. Sun sought treatment nationwide, endured endless suffering, yet couldn’t defeat the chameleon of the tumor world – diffuse large B-cell lymphoma.
“It’s tough. Prepare yourself mentally.” “I want to live to see my child go to university.”
🍋Seeking a glimmer of hope, he turned to Zhejiang University Hospital in Hangzhou. This time, the doctors said, “Let’s give it a try together.”
Multiple abdominal lymphoma lesions invading the intestinal wall, multiple rounds of chemo couldn’t stop the lymphoma from spreading everywhere. Intestinal wall invasion by lymphoma is a relative contraindication for CAR-T therapy, as it can lead to intestinal perforation, so he was no longer suitable for traditional CAR-T cell therapy.
🌿Prof. Liu Mingyao’s team and Prof. Huang He’s team used the Nobel Prize-winning CRISPR/Cas9 gene editing technology to precisely knock out the PD1 site in T lymphocytes and insert the targeted CD19 CAR molecule for tumor cells, creating a brand-new non-viral targeted integrated CAR-T cell (PD1-19bbz), and successfully completed Phase I clinical trials in humans for the first time, verifying the safety and efficacy of the new CAR-T cells.
💪The brand-new PD1-19bbz CAR-T cells, with a low risk of cytokine storms and other complications, gave Mr. Sun a new lease on life.
👑Mr. Sun received PD1-19bbz CAR-T cell infusion and returned. Fourteen days after CAR-T cell return, all indicators were normal. After evaluation, he was discharged. One month after the return, PET-CT evaluation showed that the large mass of tumor invading the intestinal mucosa in the original abdominal cavity had completely disappeared.
🏸Today, Mr. Sun has been disease-free for over 2 years.
In a recent follow-up, all of Sun’s examination results were normal, his weight had increased significantly compared to before his illness, and his complexion looked much healthier. “After cell therapy, my body suddenly felt normal again. My friends and family all say I’ve miraculously recovered. Now in my spare time, I even play badminton, completely restoring my pre-illness lifestyle.”
Tsinghua University
🎨Two years later, in the summer of 2022, Mr. Sun shared good news with the medical staff in Hangzhou: his child has been accepted to the School of Arts at Tsinghua University!
🎉To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!
Email: doctor.huang@globecancer.com,
WhatsApp: +8613717959070
🌿 #MiracleRebirth #CRISPR #CARTCellTherapy #ZhejiangUniversity #TsinghuaUniversity #MedicalBreakthroughs #CancerTreatment